170 related articles for article (PubMed ID: 22573348)
1. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression.
Feng S; Shao L; Yu W; Gavine P; Ittmann M
Clin Cancer Res; 2012 Jul; 18(14):3880-8. PubMed ID: 22573348
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
3. FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.
Yu W; Feng S; Dakhova O; Creighton CJ; Cai Y; Wang J; Li R; Frolov A; Ayala G; Ittmann M
Clin Cancer Res; 2011 Jul; 17(13):4355-66. PubMed ID: 21622724
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
5. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
7. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
Wang J; Stockton DW; Ittmann M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6169-78. PubMed ID: 15448004
[TBL] [Abstract][Full Text] [Related]
8. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
9. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.
Wang J; Yu W; Cai Y; Ren C; Ittmann MM
Neoplasia; 2008 Aug; 10(8):847-56. PubMed ID: 18670643
[TBL] [Abstract][Full Text] [Related]
10. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.
Wang Y; Pan Y; Lv Z; Gou S
Eur J Med Chem; 2024 May; 271():116415. PubMed ID: 38643670
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
13. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
[TBL] [Abstract][Full Text] [Related]
15. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
[TBL] [Abstract][Full Text] [Related]
17. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
18. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
